Radiosurgery for Spasticity
(SPASM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to help individuals with spasticity, characterized by very tight muscles. The treatment, called stereotactic radiosurgery dorsal rhizotomy, uses precise radiation beams aimed at nerves in the back to relax the muscles. Participants will be randomly assigned to either a real treatment group or a "sham" group (a control group that does not receive the actual treatment) to determine the real treatment's effectiveness. Individuals with long-term spasticity unresponsive to medication might be suitable for this trial. After six months, those in the sham group can opt to receive the real treatment. As an unphased trial, this study provides a unique opportunity for patients to explore innovative treatment options that might not be available elsewhere.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial is for people whose spasticity is not helped by their current medications, you might be able to continue them. It's best to ask the trial organizers for more details.
What prior data suggests that stereotactic radiosurgery dorsal rhizotomy is safe for treating spasticity?
Research shows that stereotactic radiosurgery dorsal rhizotomy uses precise radiation beams to target specific nerves in the back, aiming to reduce muscle stiffness, or spasticity. Studies on similar treatments have shown they can effectively reduce spasticity.
While direct safety data for this exact procedure is unavailable, similar treatments like selective dorsal rhizotomy have managed spasticity in children and young adults. These treatments are generally well-tolerated, though they can have side effects, as with any medical procedure.
The current trial does not focus on testing the treatment's safety in a new phase, indicating that the safety of this type of treatment is already somewhat understood. However, participants should discuss any concerns with their healthcare provider to understand potential risks.12345Why are researchers excited about this trial?
Researchers are excited about the potential of stereotactic radiosurgery dorsal rhizotomy for treating spasticity because it offers a non-invasive approach, unlike traditional surgical options like selective dorsal rhizotomy. This treatment uses precise radiation to target the nerves responsible for muscle overactivity, potentially reducing spasticity without the need for incisions or long recovery times. By focusing radiation on specific neural pathways, it aims to provide relief with minimal side effects, which could be a game-changer for patients seeking alternatives to surgery or invasive procedures.
What evidence suggests that stereotactic radiosurgery dorsal rhizotomy is effective for spasticity?
In this trial, participants will receive either stereotactic radiosurgery dorsal rhizotomy (SRS) or a sham treatment. Research shows that SRS uses precise radiation to target specific nerves, helping to reduce muscle tightness. This treatment builds on the well-known procedure called selective dorsal rhizotomy (SDR), which reduces muscle stiffness in conditions like cerebral palsy. Studies have shown that SDR effectively lowers muscle stiffness and improves movement in children and young adults. The radiosurgery version aims to achieve similar results with a less invasive approach. Overall, early findings suggest it could be a promising option for easing muscle stiffness.12456
Who Is on the Research Team?
Joshua Palmer, MD
Principal Investigator
Ohio State University
Are You a Good Fit for This Trial?
This trial is for individuals over 16 years old with chronic spasticity from conditions like stroke, SCI, or cerebral palsy that doesn't improve with medication. If under 18, parental consent is needed. It's not for those who can't lie on their back for the procedure, if the target nerve isn't visible on scans, or if pregnant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either stereotactic radiosurgery dorsal rhizotomy or a sham treatment
Follow-up
Participants are monitored for changes in spasticity and quality of life
Crossover Treatment
Participants who received the sham treatment are eligible to receive the real treatment
Long-term Follow-up
Participants are monitored for long-term changes in spasticity-related quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Sham
- Stereotactic Radiosurgery Dorsal Rhizotomy
Stereotactic Radiosurgery Dorsal Rhizotomy is already approved in United States, European Union for the following indications:
- Spasticity associated with stroke
- Spasticity associated with spinal cord injury
- Spasticity associated with cerebral palsy
- Spasticity in children with cerebral palsy
- Spasticity in adults with spinal cord injury
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor
Centro Diagnostico Milano, Co-PI: Pantaleo Romanelli, MD
Collaborator
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester